We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Events

09 Apr 2024 - 12 Apr 2024
15 Apr 2024 - 17 Apr 2024
23 Apr 2024 - 26 Apr 2024

Establishment of Biomarker Panel May Lead to Rapid Tests for Early Diagnosis of Pancreatic Cancer

By LabMedica International staff writers
Posted on 10 Apr 2016
Print article
Image: Micrograph of pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) (Photo courtesy of Wikimedia Commons).
Image: Micrograph of pancreatic ductal adenocarcinoma (the most common type of pancreatic cancer) (Photo courtesy of Wikimedia Commons).
A panel comprising five genetic biomarkers was shown to accurately differentiate among tissues from pancreatic tumors and those taken from various non-malignant sources.

Investigators at Beth Israel Deaconess Medical Center (Boston, MA, USA) applied innovative data normalization and gene selection approaches to analyze a number of publicly available pancreatic cancer gene expression datasets. They combined the statistical power of multiple genomic studies while masking their variability and batch effects to identify robust early diagnostic biomarkers of pancreatic cancer.

The investigators established a panel comprising the genes TMPRSS4 (Transmembrane protease, serine 4), AHNAK2 (AHNAK nucleoprotein 2), POSTN (Periostin), ECT2 (Epithelial cell transforming 2), and SERPINB5 (Serpin peptidase inhibitor, clade B (ovalbumin), member 5) that achieved on average 95% sensitivity and 89% specificity in discriminating pancreatic ductal adenocarcinoma (PDAC) from non-tumor samples in four training sets and similar performance in five independent validation datasets. The five-gene classifier accurately discriminated PDAC from chronic pancreatitis, other cancers, and non-tumor samples from PDAC precursors in three independent datasets.

PDAC-specific expression of the biomarker panel was measured by qRT-PCR (qualitative real-time PCR) in microdissected patient-derived FFPE (formalin-fixed, paraffin-embedded) tissues. Cell-based assays were then used to assess the impact of two of the biomarkers, TMPRSS4 and ECT2, on PDAC cells.

Results revealed that knock-down of TMPRSS4 and ECT2 reduced PDAC soft agar growth and cell viability, and TMPRSS4 knockdown also blocked PDAC migration and invasion.

“Pancreatic cancer is a devastating disease with a death rate close to the incidence rate,” said senior author Dr. Towia Libermann, professor of medicine at Beth Israel Deaconess Medical Center. “Because more than 90% of pancreatic cancer cases are diagnosed at the metastatic stage, when there are only limited therapeutic options, earlier diagnosis is anticipated to have a major impact on extending life expectancy for patients. There has been a lack of reliable markers, early indicators, and risk factors associated with pancreatic cancer, but this new way of differentiating between healthy and malignant tissue offers hope for earlier diagnosis and treatment.”

“Because these five genes are turned on so early in the development of pancreatic cancer, they may play roles as drivers of this disease and may be exciting targets for therapies,” said Dr. Libermann. “Moving forward, we will explore the potential to convert this tissue-based diagnostic into a noninvasive blood or urine test.”

The study was published in the March 16, 2016, online edition of the journal Oncotarget.

Related Links:

Beth Israel Deaconess Medical Center


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
One Step HbA1c Measuring System
GREENCARE A1c
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: Reaching speeds up to 6,000 RPM, this centrifuge forms the basis for a new type of inexpensive, POC biomedical test (Photo courtesy of Duke University)

POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection

Exosomes, tiny cellular bioparticles carrying a specific set of proteins, lipids, and genetic materials, play a crucial role in cell communication and hold promise for non-invasive diagnostics.... Read more

Molecular Diagnostics

view channel
Image: MOF materials efficiently enrich cfDNA and cfRNA in blood through simple operational process (Photo courtesy of Science China Press)

Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis

The ability to diagnose diseases early can significantly enhance the effectiveness of clinical treatments and improve survival rates. One promising approach for non-invasive early diagnosis is the use... Read more

Hematology

view channel
Image: The low-cost portable device rapidly identifies chemotherapy patients at risk of sepsis (Photo courtesy of 52North Health)

POC Finger-Prick Blood Test Determines Risk of Neutropenic Sepsis in Patients Undergoing Chemotherapy

Neutropenia, a decrease in neutrophils (a type of white blood cell crucial for fighting infections), is a frequent side effect of certain cancer treatments. This condition elevates the risk of infections,... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.